| Literature DB >> 29720274 |
Fabian Uddén1, Matuba Filipe2, Åke Reimer1,3, Maria Paul1, Erika Matuschek4, John Thegerström1, Sven Hammerschmidt5, Tuula Pelkonen6, Kristian Riesbeck7.
Abstract
BACKGROUND: Chronic suppurative otitis media (CSOM) is an important cause of hearing loss in children and constitutes a serious health problem globally with a strong association to resource-limited living conditions. Topical antibiotics combined with aural toilet is the first-hand treatment for CSOM but antimicrobial resistance and limited availability to antibiotics are obstacles in some areas. The goal of this study was to define aerobic pathogens associated with CSOM in Angola with the overall aim to provide a background for local treatment recommendations.Entities:
Keywords: Chronic suppurative otitis media; Enterobacteria; Infection; Otitis media; Proteus; Pseudomonas aeruginosa
Mesh:
Year: 2018 PMID: 29720274 PMCID: PMC5932871 DOI: 10.1186/s40249-018-0422-7
Source DB: PubMed Journal: Infect Dis Poverty ISSN: 2049-9957 Impact factor: 4.520
Fig. 1a Map of Angola and its provinces [39] (by Golbez used under CC BY 2.5, https://creativecommons.org/licenses/by/2.5/). b Location map of Angola in Africa [40] (by TUBS used under CC BY-SA 3.0, https://creativecommons.org/licenses/by-sa/3.0/)
Demographics of the study population and numbers of samples collected and pathogens isolated with regard to age group
| Age group (years) | Gender (male/female)1 | Ear discharge samples | Nasopharyngeal samples | Total | Corresponding isolates3 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| Isolates2 |
| Isolates2 |
| Isolates2 | Ear/Ear | Ear/Nph | |||
| < 5 | 34 (22) | 20/14 | 44 | 124 (2.8 [0–5]) | 34 | 104 (3.1 [1–6]) | 78 | 194 (2.5 [0–6]) | 10 (18.2) | 7 (10) |
| 5–9 | 23 (15) | 15/8 | 26 | 81 (3.1 [0–6]) | 23 | 52 (2.3 [0–3]) | 49 | 117 (2.4 [0–6]) | 7 (36.8) | 3 (8.3) |
| 10–14 | 24 (16) | 16/8 | 31 | 97 (3.1 [1–7]) | 24 | 51 (2.1 [0–5]) | 55 | 144 (2.6 [0–7]) | 15 (33.3) | 6 (12.8) |
| ≥ 15 | 55 (36) | 33/22 | 66 | 184 (2.8 [1–6]) | 54 | 109 (2.0 [0–4]) | 120 | 286 (2.4 [0–6]) | 18 (29.5) | 11 (10.8) |
| No age data | 16 (11) | 7/4 | 17 | 48 (2.8 [1–4]) | 16 | 45 (2.8 [1–4]) | 33 | 96 (2.9 [1–4]) | 2 (28.6) | 0 |
| Total | 152 | 91/56 | 1844 | 534 (2.9 [0–7]) | 1515 | 361 (2.4 [0–6]) | 335 | 823 (2.5 [0–7]) | 52 (27.3) | 27 (9.3) |
No data about age or gender was available for 16 and 5 patients, respectively
1 Gender data was missing for 5 patients
2 Presented as N (mean number of isolates per sample [range])
3 Number of species present in two ear discharge samples, or in samples from ear discharge and the nasopharynx, from the same patient. Presented as N (%)
4 Bilateral samples were collected from 32 patients
5 No nasopharyngeal sample was collected from 1 patient
Microbiological findings in samples from ear discharge and the nasopharynx
| Isolates from ear discharge ( | Isolates from nasopharynx ( | ||
|---|---|---|---|
| Pathogen | Pathogen | ||
| 79 (14.7) | CoNS | 90 (30.7) | |
|
| 71 (13.2) | 47 (16.0) | |
| 47 (8.8) |
| 32 (10.9) | |
| 42 (7.8) |
| 24 (8.2) | |
| CoNS | 39 (7.3) | 12 (4.1) | |
| 31 (5.8) |
| 10 (3.4) | |
|
| 24 (4.5) | 10 (3.4) | |
|
| 19 (3.5) | 8 (2.7) | |
| 18 (3.4) | 6 (2.0) | ||
| 16 (3.0) |
| 6 (2.0) | |
| 15 (2.8) |
| 5 (1.7) | |
|
| 14 (2.6) | 4 (1.4) | |
| Other | 12 (2.2) | Fungi | 4 (1.4) |
| Fungi | 12 (2.2) |
| 4 (1.4) |
|
| 12 (2.2) |
| 3 (1.0) |
|
| 11 (2.0) | 3 (1.0) | |
| 11 (2.0) | Other2 | 21 (7.2) | |
| 10 (1.9) | No growth | 4 (1.4) | |
| 7 (1.3) | |||
|
| 6 (1.1) | ||
| Other1 | 38 (7.1) | ||
| No growth | 3 (0.6) | ||
Pathogens representing less than 1% of isolates in each group have been pooled as “Other”. CoNS = coagulase-negative staphylococci
1 Included pathogens listed from most to least prevalent: Stenotrophomonas maltophilia, Acinetobacter spp., Gemella morbillorum, Bordetella trematum, Globicatella sulfidifaciens, Aeromonas caviae, Escherichia hermannii, Streptococcus pneumoniae, Aerococcus viridans, Arcanobacterium haemolyticum, Dermabacter hominis, Kocuria spp., Microcuccus spp., Weeksella virosa, Raoultella ornithinolytica, Serratia marcescens, Lactococcus lactis, Weisella confusa, Neisseria meningitidis
2 Included pathogens listed from most to least prevalent: Klebsiella spp., Aerococcus viridans, Lactococcus lactis, Leuconostoc spp., Macrococcus caseolyticus, Moraxella nonliquefaciens, Raoultella ornithinolytica, Streptococcus spp., Citerobacter koseri, Morganella morganii, Serratia marcescens, Dietzia maris, Lactobacillus salivarius, Shewanella putrefaciens, Stenotrophomonas maltophilia
Pneumococccal serotypes identified in 34 isolates
| Serotype |
| (%) |
|---|---|---|
| 19F* | 4 | (11.8) |
| 6A* | 3 | (8.8) |
| 17F | 3 | (8.8) |
| 16 | 2 | (5.9) |
| 21 | 2 | (5.9) |
| 38 | 2 | (5.9) |
| 11A | 2 | (5.9) |
| 23B | 2 | (5.9) |
| NT | 2 | (5.9) |
| 4* | 1 | (2.9) |
| 18C* | 1 | (2.9) |
| 19A* | 1 | (2.9) |
| 23F* | 1 | (2.9) |
| 6B* | 1 | (2.9) |
| 15A | 1 | (2.9) |
| 15C | 1 | (2.9) |
| 19B | 1 | (2.9) |
| 12 | 1 | (2.9) |
| 13 | 1 | (2.9) |
| 20 | 1 | (2.9) |
| 34 | 1 | (2.9) |
| Total | 34 | (100) |
| Total PCV13-serotypes | 12 | (35.3) |
Asterisks indicate serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13). NT = non-typeable
Susceptibility of gram-negative bacterial species to selected antimicrobial agents
| Antimicrobial agent | Susceptibility1 | non- | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| (%) |
| (%) |
| (%) |
| (%) |
| (%) | ||
| Amoxicillin | S | 4 | (80) | ||||||||
| R | 1 | (20) | |||||||||
| Piperacillin-tazobactam | S | 88 | (98.9) | 125 | (95.4) | 61 | (96.8) | ||||
| I | 5 | (3.8) | |||||||||
| R | 1 | (1.1) | 1 | (0.8) | 2 | (3.2) | |||||
| Cefotaxime | S | 88 | (98.9) | 121 | (92.3) | 5 | (100) | 9 | (100) | ||
| I | 1 | (0.8) | |||||||||
| R | 1 | (1.1) | 9 | (6.9) | |||||||
| Ceftazidime | S | 88 | (1.1) | 122 | (93.1) | 62 | (98.4) | ||||
| I | 2 | (1.5) | |||||||||
| R | 1 | (1.1) | 7 | (5.3) | 1 | (1.6) | |||||
| Imipenem | S | 89 | (100) | 122 | (93.1) | 60 | (95.2) | ||||
| I | 9 | (6.9) | 3 | (4.8) | |||||||
| Meropenem | S | 89 | (100) | 131 | (100) | 52 | (82.5) | 5 | (100) | 9 | (100) |
| I | 11 | (17.5) | |||||||||
| Ciprofloxacin | S | 76 | (85.4) | 105 | (80.2) | 58 | (92.1) | 5 | (100) | 9 | (100) |
| I | 3 | (3.4) | 7 | (5.3) | 1 | (1.6) | |||||
| R | 10 | (11.2) | 19 | (14.5) | 4 | (6.3) | |||||
| Gentamicin | S | 63 | (70.8) | 106 | (80.9) | 58 | (92.1) | ||||
| I | 3 | (3.4) | 3 | (2.3) | 1 | (1.6) | |||||
| R | 23 | (25.8) | 22 | (16.8) | 4 | (6.3) | |||||
| Tobramycin | S | 72 | (80.9) | 109 | (83.2) | 59 | (93.7) | ||||
| I | 5 | (5.6) | 13 | (9.9) | |||||||
| R | 12 | (13.5) | 9 | (6.9) | 4 | (6.3) | |||||
| Tetracycline | S | 4 | (80) | 7 | (77.8) | ||||||
| R | 1 | (20) | 2 | (22.2) | |||||||
| Trimethoprim-sulfamethoxazole | S | 31 | (34.8) | 71 | (54.2) | 2 | (40) | 1 | (11.1) | ||
| I | 2 | (2.2) | 2 | (1.5) | 1 | (11.1) | |||||
| R | 56 | (62.9) | 58 | (44.3) | 3 | (60) | 7 | (77.8) | |||
| Chloramphenicol | S | 27 | (57.4) | ||||||||
| R | 20 | (42.6) | 42 | (100) | |||||||
| Colistin | S | 263 | (55.3) | 404 | (95.2) | ||||||
| R | 702 | (100) | 213,5 | (44.7) | 24,6 | (4.8) | |||||
Isolates grouped as non-Proteus Enterobacteriaceae were 38 Providencia spp., 25 Morganella morganii, 18 Klebsiella spp., 18 Citrobacter spp., 13 Enterobacter spp., 13 Escherichia spp., 3 Pantoea agglomerans, 2 Serratia marcescens and 1 Raoultella ornithinolytica
1 S, susceptible; I, intermediate; R, resistant
2 Susceptibility testing for Proteus spp. against colistin was done with 70 randomly selected isolates
3 Susceptibility testing for non-Proteus Enterobacteriaceae against chloramphenicol and colistin was done with 47 randomly selected isolates
4 Susceptibility testing for P. aeruginosa against chloramphenicol and colistin was done with 42 randomly selected isolates
5 All MIC ≥64 mg/L including Providencia, Morganella, Enterobacter and Serratia spp.
6 All MIC = 4 mg/L
Susceptibility of gram-positive bacterial species to selected antimicrobial agents
| Antimicrobial agent | Susceptibility1 |
|
|
| |||
|---|---|---|---|---|---|---|---|
| ( | ( | ( | |||||
|
| (%) |
| (%) |
| (%) | ||
| Benzylpenicillin | S | 15 | (46.9) | 9 | (100) | ||
| R | 17 | (53.1) | |||||
| Cefoxitin2 | S | 6 | (46.2) | ||||
| R | 7 | (53.8) | |||||
| Norfloxacin3 | S | 32 | (100) | 9 | (69.2) | ||
| R | 4 | (30.8) | |||||
| Tobramycin | S | 4 | (30.8) | ||||
| R | 9 | (69.2) | |||||
| Erythromycin | S | 32 | (100) | 9 | (100) | 12 | (92.3) |
| R | 1 | (7.7) | |||||
| Clindamycin | S | 32 | (100) | 9 | (100) | 11 | (84.6) |
| I | 1 | (7.7) | |||||
| R | 1 | (7.7) | |||||
| Tetracycline | S | 24 | (75) | 3 | (33.3) | ||
| I | 1 | (3.1) | |||||
| R | 7 | (21.9) | 6 | (66.7) | |||
| Fusidic acid | S | 13 | (100) | ||||
| Rifampicin | S | 27 | (84.4) | ||||
| R | 5 | (15.6) | |||||
| Trimethoprim-sulfamethoxazole | S | 6 | (18.8) | 13 | (100) | ||
| I | 1 | (3.1) | |||||
| R | 25 | (78.1) | |||||
1 S, susceptible; I, intermediate; R, resistant
2 Screening substance for methicillin resistance
3 Screening substance for quinolone resistance